BioNTech (BNTX) Set to Announce Earnings on Monday

BioNTech (NASDAQ:BNTX) is set to post its quarterly earnings results before the market opens on Monday, November 4th. Analysts expect BioNTech to post earnings of ($1.06) per share for the quarter. BioNTech has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same quarter in the prior year, the company posted ($0.86) earnings per share. The company’s revenue for the quarter was down 23.3% on a year-over-year basis. On average, analysts expect BioNTech to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

BioNTech Trading Down 1.1 %

BNTX stock opened at $110.48 on Monday. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The firm has a market cap of $26.26 billion, a P/E ratio of 220.96 and a beta of 0.24. The business’s 50 day moving average is $107.26 and its 200-day moving average is $94.98. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. HC Wainwright upped their price objective on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, October 7th. JPMorgan Chase & Co. raised BioNTech from an “underweight” rating to a “neutral” rating and boosted their target price for the stock from $91.00 to $125.00 in a report on Monday, September 16th. Hsbc Global Res raised BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. UBS Group boosted their target price on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Finally, Jefferies Financial Group raised BioNTech from a “hold” rating to a “buy” rating and boosted their target price for the stock from $96.00 to $150.00 in a report on Tuesday, September 17th. Five analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $135.54.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.